molecules of the month

S62798 (Servier)

fibrinolytic TAFIa carboxypeptidase inhibitor

Ph. II candidate for pulm. embolism; discont.

from literature pharmacophore and SBDD

J. Med. Chem., Mar. 25, 2021

Servier, Croissy-sur-Seine, FR

1 min read

The Servier thrombin activatable fibrinolysis inhibitor (TAFIa) inhibitor (S62798) is a fibrinolytic (clot degrading) agent which entered Ph. II in the EU for pulmonary embolism, but development appears to have been cancelled. TAFIa inhibitors are suggested to reduce clotting risk without  the risk of major hemorrhage since they don’t interfere with platelet activation and blood coagulation. The phosphinic acid acts as a zinc binding motif, and was cyclized in order to reduce conformational flexibility and increase selectivity against other carboxypeptidases. This phosphorus-containing molecule has interesting drug properties as it is a highly polar, renally excreted compound possessing two acidic sites and multiple potentially basic atoms. The binding mode is also interesting with numerous highly polar interactions including zinc metal-binding within a short…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: